| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 15.00M | 5.00M | 50.00M | 0.00 |
| Gross Profit | 14.95M | 5.00M | 50.00M | -78.00K |
| EBITDA | -185.46M | -163.75M | -27.03M | -75.12M |
| Net Income | -176.97M | -156.99M | -37.12M | -119.28M |
Balance Sheet | ||||
| Total Assets | 293.08M | 369.97M | 68.18M | 74.58M |
| Cash, Cash Equivalents and Short-Term Investments | 273.28M | 350.77M | 56.86M | 67.21M |
| Total Debt | 1.01M | 1.00M | 21.11M | 1.53M |
| Total Liabilities | 53.46M | 57.51M | 293.90M | 266.87M |
| Stockholders Equity | 239.63M | 312.46M | -225.72M | -192.29M |
Cash Flow | ||||
| Free Cash Flow | -148.50M | -119.81M | -30.55M | -67.85M |
| Operating Cash Flow | -148.41M | -119.67M | -30.53M | -65.65M |
| Investing Cash Flow | -229.06M | -30.55M | -17.00K | -2.20M |
| Financing Cash Flow | 237.65M | 412.96M | 20.12M | 59.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $834.17M | ― | -36.50% | ― | 30.95% | -78.41% | |
53 Neutral | $892.84M | -9.26 | -52.56% | ― | ― | 26.68% | |
52 Neutral | $1.10B | ― | -88.40% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $849.23M | -14.98 | -52.82% | ― | 53.23% | 35.32% | |
51 Neutral | $993.21M | ― | ― | ― | 1049.81% | 7.85% | |
47 Neutral | $817.02M | -5.22 | ― | ― | 10.85% | -1.41% |
On October 7, 2025, Zenas BioPharma entered into a license agreement with InnoCare Pharma, granting Zenas exclusive rights to develop and commercialize several small molecule compounds, including orelabrutinib, a BTK inhibitor for multiple sclerosis. This agreement positions Zenas to potentially transform the treatment landscape for progressive MS, with a Phase 3 trial for orelabrutinib already initiated. The deal also includes a $35 million upfront payment and potential milestone payments, reflecting Zenas’s strategic expansion in the autoimmune treatment market.
The most recent analyst rating on (ZBIO) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.
On September 2, 2025, Zenas BioPharma entered into a $300 million funding agreement with Royalty Pharma, granting them rights to revenue streams from the sales of obexelimab. This deal provides Zenas with financial support to advance obexelimab’s development and potential commercial launch, particularly for treating IgG4-Related Disease, and underscores the drug’s potential as a significant player in the autoimmune disease market.
The most recent analyst rating on (ZBIO) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.
Zenas BioPharma, Inc. faces significant business risks due to securities class action litigation, which can arise after fluctuations in their stock prices. In April 2025, a lawsuit was filed against the company and its executives, alleging violations of the Securities Act of 1933 related to their IPO. This litigation demands compensatory damages and legal fees, potentially diverting management’s focus and increasing operational costs. Furthermore, the situation could elevate the cost of liability insurance for directors and officers, impacting the company’s financial health and reliance on its balance sheet for covering legal expenses.
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing transformative therapies for autoimmune diseases, with a lead product candidate, obexelimab, designed to inhibit B cell activity without depleting them.